Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone

International Journal of Oncology

Volumn 31, Issue 5, 2007, Pages 1223-1230

  Sotomayor, Sandra ^a   Carmena, María J ^a   Schally, Andrew V ^b,c   Varga, Jozsef L ^b,c   Sánchez Chapado, Manuel ^a,d   Prieto, Juan C ^a   Bajo, Ana M ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Growth hormone releasing hormone analogs; HER2; HER3; Prostate cancer; Vasoactive intestinal peptide receptors

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB2 PROTEIN, HUMAN; GROWTH HORMONE RELEASING FACTOR; MESSENGER RNA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ARTICLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RNA, MESSENGER; VASOACTIVE INTESTINAL PEPTIDE;

EID: 38449095743     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Nagy A and Schally AV: Targeting of cytotoxic luteinizing hormone-analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 73: 851-859, 2005.
3. Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G and Rekasi Z: Peptide analogs in the therapy of prostate cancer. Prostate 45: 158-166, 2000.
4. Collado B, Carmena MJ, Sanchez-Chapado M, Ruiz-Villaespesa A, Bajo AM, Fernandez-Martinez AB, Varga JL, Schally AV and Prieto JC: Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int J Oncol 26: 1629-1635, 2005.
5. Said SI: Vasoactive intestinal peptide. Biological role in health and disease. Trends Endocrinol Metab 2: 107-112, 1992.
6. Gkonos PJ, Ashby MH and Andrade AA: Vasoactive intestinal peptide stimulates prostate-specific antigen secretion by LNCaP prostate cancer cells. Regul Pept 65: 153-157, 1996.
7. Collado B, Gutiérrez-Cañas I, Rodríguez-Henche N, Prieto JC and Carmena MJ: Vasoactive intestinal peptide increases vascular growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul Pept 119: 69-75, 2004.
8. Collado B, Sánchez-Chapado M, Prieto JC and Carmena MJ: Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells. Mol Cell Endocrinol 249: 116-122, 2006.
9. Gutiérrez-Cañas I, Juarranz MG, Collado B, Rodríguez-Henche N, Chiloeches A, Prieto JC and Carmena MJ: Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK and PI3K. Prostate 63: 44-55, 2005.
10. Hoosein NM, Logothetis CJ and Chung IWK: Differential effects of peptide hormones, bombesin, vasoactive intestinal polypeptide and somatostatin analogue RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 149: 1209-1213, 1993.
11. Sastry KS, Smith AJ, Karpova Y, Datta SR and Kulik G: Diverse antiapoptotic signaling pathways activated by vasoactive intestinal polypeptide, epidermal growth factor, and phosphatidylinositol 3-kinase in prostate cancer cells converge on BAD. J Biol Chem 281: 20891-20901, 2006.
12. 1 subtype is predominant in rat prostate membranes. Prostate 1: 1-6, 1999.
13. Laburthe M and Couvineau A: Molecular pharmacology and structure of PACAP receptors for VIP and PACAP. Regul Pept 108: 165-173, 2002.
14. García-Fernández MO, Solano RM, Carmena MJ, Busto R, Bodega G, Ruíz-Villaespesa A and Sánchez-Chapado M: Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides 24: 893-902, 2003.
15. Gutiérrez-Cañas I, Rodríguez-Henche N, Bolaños O, Carmena MJ, Prieto JC and Juarranz MG: VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. Br J Pharmacol 139: 1050-1058, 2003.
16. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
17. Richards J: New signaling pathways for hormones and cyclic adenosine 3',5'-monophosphate action in endocrine cells. Mol Endocrinol 15: 209-218, 2002.
18. Stork PJS and Schmitt JM: Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12: 258-266, 2002.
19. Rekasi Z, Varga JL, Schally AV, Halmos G, Groot K and Czompoly T: Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro. Proc Natl Acad Sci USA 97: 1218-1223, 2000.
20. Varga JL, Schally AV, Csernus VJ, Zarandi M, Halmos G, Groot K and Rekasi Z: Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci USA 96: 692-697, 1999.
21. Plonowski A, Varga JL, Schally AV, Krupa M, Groot K and Halmos G: Inhibition of PC-3 human prostate cancers by analogs of growth-hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. Int J Cancer 98: 624-629, 2002.
22. Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S and Baselga J: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/ HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283, 2003.
23. Yarden Y and Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
24. Freeman MR: HER2/HER3 heterodimers in prostate cancer: whither HER1/EGFR? Cancer Cell 6: 427-428, 2004.
25. Alroy I and Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410: 83-86, 1997.
26. El Sheik SS, Domin J, Abel P, Stamp G and Lalani EN: Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 6: 846-853, 2004.
27. Robert D and Mass MD: The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys 58: 932-940, 2004.
28. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M and Yarden Y: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467, 1996. (Pubitemid 26151185)
29. Yen L, Benlimame N, Nie ZR, Xiao D, Wang T, Al Moustafa AE, Esumi H, Milanini J, Hynes NE, Pages G and Alaoui-Jamali MA: Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Cell Biol 13: 4044-4049, 2002.
30. Di Lorenzo G, Tortora G, D'Armiento FP, De Laurentiis M, Placido SD, Catalano G, Bianco AR and Ciardiello F: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen- independence in human prostate cancer. Clin Cancer Res 8: 3438-3444, 2002.
31. Carles J, Lloreta J, Salido M, Font A, Suárez M, Baena V, Nogué M, Doménech M and Fabregat X: Her-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res 10: 4742-4745, 2004.
32. Wen Y, Hu M, Makino K, Spohn B, Bartholomeusz G and Yan DH: HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60: 6841-6845, 2000.
33. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC and Loda M: Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 66: 5723-5728, 2006.
34. Formento P, Hannoun-Levi JM, Fischel JL, Magné N, Etienne-Grimaldi MC and Milano G: Dual HER1-2 targeting of hormone-refractory prostate cancer by ZD1389 and trastuzumab. Eur J Cancer 40: 2837-2844, 2004.
35. Bellezza I, Bracarda S, Caserta C and Minelli A: Targeting of EGFR tyrosine kinase by ZD1839 ('Iressa') in androgen-responsive prostate cancer in vitro. Mol Genet Metab 88: 114-122, 2006.
36. He H, Levitzki A, Zhu HJ, Walker F, Burgess A and Maruta H: Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases. J Biol Chem 276: 26741-26744, 2001.
37. s protein-coupled receptor agonist induce transactivation of the epidermal growth factor receptor in T84 cells. J Biol Chem 279: 6271-6279, 2004.
38. Chang JT, Chen IH, Liao CT, Wang HM, Hsu YM, Hung KF, Lin CJ, Hsieh LL and Cheng AJ: A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem 35: 591-596, 2002.
39. Rekasi Z, Varga JL, Schally AV, Halmos G, Armatis P, Groot K and Czompoly T: Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. Endocrinology 141: 2120-2128, 2000.
40. Brys M, Stawinska M, Foksinski M, Barecki A, Zydec C, Miekos E and Krajewska WM: Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms. Oncol Rep 11: 219-224, 2004.
41. Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'Armiento M, Bianco AR and De Placido S: HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori 90: 163-170, 2004.
42. Rau KM, Kang HY, Cha TL, Miller SA and Hung MC: The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Rel Cancer 12: 511-532, 2005.
43. Kuwahara I, Lillehoj EP, Lu W, Singh IS, Isohama Y, Miyata T and Kim KC: Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-κB activation via EGFR transactivation in a lung epithelial cell line. Am J Physiol Lung Cell Mol Physiol 291: L407-L416, 2006.
44. Leserer M, Gschwind A and Ulrich A: Epidermal growth factor receptor signal transactivation. IUBMB Life 49: 405-409, 2000.
45. Hsieh M and Conti M: G-protein-coupled receptor signaling and the EGF network in endocrine systems. Trends Endocrinol Metab 16: 320-326, 2005.
46. Wetzker R and Bohmer FD: Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4: 651-657, 2003.